Rahma 2012.

Methods	Uncontrolled phase II study
Participants	21 ovarian cancer patients without evidence of disease after prior therapy
Interventions	Subcutaneous short peptide (p53) vs intravenous peptide‐pulsed dendritic cells (p53) Adjuvant: Montanide ISA‐51 and GM‐CSF (only in cohort treated with peptide)
Outcomes	Survival (progression‐free survival, overall survival) Tumour responses Immune responses: cellular Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’